Refractory psychosis and prominent cognitive deficits in a patient with mega-cisterna magna

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 561-563

  Ferentinos, Panayotis P ^a   Kontaxakis, Vassilis P ^a   Havaki Kontaxaki, Beata J ^a   Paplos, Konstantinos G ^a   Pappa, Dimitra A ^a   Soldatos, Constantin R ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amisulpride; Cerebellum; Cognitive deficits; Dandy Walker Complex; Galantamine; Mega cisterna magna; Psychosis

Indexed keywords

AMISULPRIDE; GALANTAMINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CEREBELLUM DISEASE; CHRONIC DISEASE; CISTERNA MAGNA; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DANDY WALKER SYNDROME; FEMALE; FOLLOW UP; HUMAN; MEGA CISTERNA MAGNA; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SOCIAL PSYCHOLOGY;

ADULT; COGNITION DISORDERS; DANDY-WALKER SYNDROME; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; PSYCHOTIC DISORDERS;

EID: 33846849198     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.10.013     Document Type: Article

References (26)

1. Allen T.B., and Mcevoy J.P. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159 (2002) 1244-1245
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (1994), American Psychiatric Association, Washington, DC
3. Andreasen N.C., O'Leary D.S., Cizadlo T., Arndt S., Rezai K., Ponto L.L., et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci U S A 93 (1996) 9985-9990
4. Andreasen N.C., Paradiso S., and O'Leary D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?. Schizophr Bull 24 (1998) 203-218
5. Arnold D.S., Rosse R.B., Dickinson D., Benham R., Deutsch S.I., and Nelson M.W. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient. J Clin Psychiatry 65 (2004) 1723-1724
6. Barkovich A.J., Kjos B.O., Norman D., and Edwards M.S. Revised classification of posterior fossa cysts and cyst like malformations based on the results of multiplanar MR imaging. Am J Roentgenol 153 (1989) 1289-1300
7. Bennouna M., Greene V.B., and Defranoux L. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenia like psychosis after traumatic brain injury. J Clin Psychopharmacol 25 (2005) 505-507
8. Bora E., Veznedaroglu B., and Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28 (2005) 139-141
9. De Filippi G., Baldwinson T., and Sher E. Nicotinic receptor modulation of neurotransmitter release in the cerebellum. Prog Brain Res 148 (2005) 307-320
10. Freudenreich O., Herz L., Deckersbach T., Evins A.E., Henderson D.C., Cather C., et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181 (2005) 358-363
11. Katsetos C.D., Hyde T.M., and Herman M.M. Neuropathology of the cerebellum in schizophrenia-an update: 1996 and future directions. Biol Psychiatry 42 (1997) 213-224
12. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
13. Langarica M., and Peralta V. Psychosis associated to megacisterna magna. An Sist Sanit Navar 28 (2005) 119-121
14. Lee M., Martin-Ruiz C., Graham A., Court J., Jaros E., Perry R., et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125 Pt 7 (2002) 1483-1495
15. Martin P., and Albers M. Cerebellum and schizophrenia: a selective review. Schizophr Bull 21 (1995) 241-250
16. Pollak L., Klein C., Rabey J.M., and Schiffer J. Posterior fossa lesions associated with neuropsychiatric symptomatology. Int J Neurosci 87 (1996) 119-126
17. Ripoll N., Bronnec M., and Bourin M. Nicotinic receptors and schizophrenia. Curr Med Res Opin 20 (2004) 1057-1074
18. Rosse R.B., and Deutsch S.I. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25 (2002) 272-275
19. Schmahmann J.D. An emerging concept. The cerebellar contribution to higher function. Arch Neurol 48 (1991) 1178-1187
20. Schmahmann J.D., and Sherman J.C. The cerebellar cognitive affective syndrome. Brain 121 Pt 4 (1998) 561-579
21. Schubert M.H., Young K.A., and Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60 (2006) 530-533
22. Sharma T., Reed C., Aasen I., and Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 85 (2006) 73-83
23. Ten Donkelaar H.J., Lammens M., Wesseling P., Thijssen H.O., and Renier W.O. Development and developmental disorders of the human cerebellum. J Neurol 250 (2003) 1025-1036
24. Turner S.J., Poole R., Nicholson M.R., and Ghadiali E.J. Schizophrenia-like psychosis and Dandy-Walker variant. Schizophr Res 48 (2001) 365-367
25. Varambally S., Venkatasubramanian G., Thirthalli J., Janakiramaiah N., and Gangadhar B.N. Cerebellar and other neurological soft signs in antipsychotic-naive schizophrenia. Acta Psychiatr Scand 114 (2006) 352-356
26. Wagner M., Quednow B.B., Westheide J., Schlaepfer T.E., Maier W., and Kuhn K.U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30 (2005) 381-390